Stock Analysis of Evaxion Biotech AS (EVAX) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code EVAX
Close 3.72
Change -0.110 / 2.87 %
Volume 6759.00
Vol Change -348.00 / 4.90 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthNeutral
Growth Index Poor Growth Stock
Value Index Poor Value Stock
Profitability Index Poor Profitability Stock
Stability Index Poor Stability Stock


Fundamental View of Evaxion Biotech AS
PE (TTM)

-0.455

Very Poor
Price / Book

-0.655

Very Poor
Price / Sales

137.10

Very Poor
Piotroski F Score

4.0

Indecisive
Market Cap

20129.14 K

Enterprise Value

23520.29 K

ROA (TTM)

3780.14

Excellent
ROE (TTM)

0

Poor
Net Margin (TTM)

-30112.70

Very Poor
Revenue

%

73112.00
Net Profit

5.63 %

-24474.00 K
Debt to Equity

-1.90

Very Poor
Altman Z Score

-17.17

Very Poor
Quick Ratio

0

Poor
Cash Ratio

0.788

Not Good


Highs/Lows of Evaxion Biotech AS
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week3.72 0 % 1.54 % 3.93.5114-May-2414-May-24
Two Week3.95 5.82 % 3.42 % 4.163.5106-May-2414-May-24
One Month4.11 9.49 % 5.60 % 4.40953.5119-Apr-2414-May-24
Three Month4.05 8.15 % 5.95 % 4.52.824320-Feb-2407-Mar-24
Six Months7.3 49.04 % 17.48 % 13.552.824324-Jan-2407-Mar-24
One year16.5 77.45 % 27.52 % 18.52.824305-Jun-2307-Mar-24
Two year18.4 79.78 % 29.70 % 31.02.824304-Oct-2207-Mar-24


Technical View of Evaxion Biotech AS
RSI

43.28

Neutral
MACD

-0.0313

Bearish
ADX

17.60

Bearish
Super Trend

3.43

Mild Bullish
Williams %R

-69.57

Neutral
CCI

-87.30

Neutral


EMA 5

3.78

Bearish
EMA 15

3.86

Strong Bearish
EMA 50

3.98

Strong Bearish
EMA 100

4.74

Strong Bearish
SMA 100

4.58

Mild Bearish
SMA 200

6.46

Mild Bearish
SMA 5 / 20

3.78 / 3.95

Mild Bearish
SMA 15 / 50

3.89 / 3.68

Bullish
SMA 50 / 200

3.68 / 6.46

Mild Bearish




Charts of Evaxion Biotech AS


Returns of Evaxion Biotech AS with Peers
Period / StockEVAXLUMOVINCCOCP
1 Week0%-12.41%-13.94%12.77%
1 Mth-9.49%0.794%-27.32%36.36%
3 Mth-8.15%-14.19%-61.85%24.52%
6mth-49.04%-16.99%2.92%15.38%
1 Year-77.45%-21.85%-57.89%-18.75%
2 Year-79.78%-66.93%-66.15%-58.52%
5 Years--82.02%--93.63%
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Evaxion Biotech AS with Peers
Ratio / StockEVAXLUMOVINCCOCP
PE-0.455-0.553-0.386-1.18
P/B-0.6550.5820.8680.664
ROA3780.14-78.48-138.27-50.90
ROE0-105.23-225.12-56.21
Debt To Equity-1.900.01030.1040.0091
Revenue73112.00
% 		1737.00 K
113951 % 		0
% 		0
%
Net Income-24474.00 K
5.63 % 		-32824.00 K
105572 % 		-48850.00 K
25.27 % 		-18021.00 K
53.60 %


Technicals of Evaxion Biotech AS with Peers
Technical / StockEVAXLUMOVINCCOCP-
ADX17.6025.9138.3136.91
CMF0.0840.211-0.0880.0226
MFI35.6363.0531.4681.52
RSI43.2842.2330.9466.83
MACD Abv SignalFalseFalseTrueTrue
Price Above 50 MATrueFalseFalseTrue-
Price Above 200 MAFalseFalseFalseTrue-


About : Evaxion Biotech AS

Address : Dr. Neergaards Vej, Horsholm, Denmark, 2970
Tel : 45 53 53 18 50
URL : https://www.evaxion-biotech.com
Code : EVAX, ISIN : US29970R1059, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 05_Feb_2021
Employee Count : 49

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase 1/2a trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy that is in pre-clinical stage for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.


Note : All Data Generated at the End of Trading Hours (EOD Data)